In summary, these results highlight the powerful diminishment of tumorigenicity via Ang-SS-Cas9/sgIGFBP5 mediated in vivo IGFBP5 gene editing, proposing the potential therapeutic target role of IGFBP5 in invasive GBM. Here, IGFBP5 is linked to glioblastoma.